CN101563097A - 用于组织损伤的干细胞生长因子疗法 - Google Patents

用于组织损伤的干细胞生长因子疗法 Download PDF

Info

Publication number
CN101563097A
CN101563097A CNA2006800458460A CN200680045846A CN101563097A CN 101563097 A CN101563097 A CN 101563097A CN A2006800458460 A CNA2006800458460 A CN A2006800458460A CN 200680045846 A CN200680045846 A CN 200680045846A CN 101563097 A CN101563097 A CN 101563097A
Authority
CN
China
Prior art keywords
scf
nucleic acid
cells
cell
transported
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800458460A
Other languages
English (en)
Chinese (zh)
Inventor
K·M·热伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENTPR PARTNERS VENTURE CAPITAL
Original Assignee
ENTPR PARTNERS VENTURE CAPITAL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ENTPR PARTNERS VENTURE CAPITAL filed Critical ENTPR PARTNERS VENTURE CAPITAL
Publication of CN101563097A publication Critical patent/CN101563097A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA2006800458460A 2005-11-14 2006-11-13 用于组织损伤的干细胞生长因子疗法 Pending CN101563097A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73705805P 2005-11-14 2005-11-14
US60/737,058 2005-11-14

Publications (1)

Publication Number Publication Date
CN101563097A true CN101563097A (zh) 2009-10-21

Family

ID=38049189

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800458460A Pending CN101563097A (zh) 2005-11-14 2006-11-13 用于组织损伤的干细胞生长因子疗法

Country Status (7)

Country Link
US (1) US8404653B2 (https=)
EP (1) EP1948246B1 (https=)
JP (1) JP2009517343A (https=)
CN (1) CN101563097A (https=)
AU (1) AU2006315601A1 (https=)
CA (1) CA2629775A1 (https=)
WO (1) WO2007059010A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114450013A (zh) * 2019-04-12 2022-05-06 爱莫里大学 用于促进造血细胞的细胞毒性的组合物和方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008118370A2 (en) * 2007-03-22 2008-10-02 The Trustees Of The University Of Pennsylvania Hyperbaric treatment in wound healing
JP5467742B2 (ja) * 2007-08-24 2014-04-09 国立大学法人 岡山大学 Ｅｃｐを有効成分とする左室リモデリングの予防及び治療剤。
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
US20150190532A1 (en) 2012-04-04 2015-07-09 The Trustees Of Columbia University In The City Of New York Smooth muscle specific inhibition for anti-restenotic therapy
GB201400562D0 (en) 2014-01-14 2014-03-05 Orla Protein Technologies Ltd Protein coated polymeric substrate
AU2016321298A1 (en) 2015-09-09 2018-03-29 The Trustees Of Columbia University In The City Of New York Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
WO2019200240A1 (en) * 2018-04-13 2019-10-17 Board Of Regents, The University Of Texas System Transmembrane stem cell factor (tm-scf) lipid nanocarriers and methods of use thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3760984A (en) * 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3923426A (en) 1974-08-15 1975-12-02 Alza Corp Electroosmotic pump and fluid dispenser including same
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4016880A (en) 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4203442A (en) * 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
US4203440A (en) * 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4210139A (en) 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US5387419A (en) * 1988-03-31 1995-02-07 The University Of Michigan System for controlled release of antiarrhythmic agents
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
DK0423980T3 (da) * 1989-10-16 2000-10-09 Amgen Inc Stamcellefaktor
US6759215B1 (en) * 1989-10-16 2004-07-06 Amgen Inc. Method of preparing human stem cell factor polypeptide
US6326198B1 (en) * 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US20030125519A1 (en) * 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5681278A (en) * 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
US5827216A (en) * 1995-06-07 1998-10-27 Cormedics Corp. Method and apparatus for accessing the pericardial space
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US5900433A (en) * 1995-06-23 1999-05-04 Cormedics Corp. Vascular treatment method and apparatus
CA2230819C (en) * 1995-08-29 2009-04-14 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprising hgf gene
GB9519776D0 (en) * 1995-09-28 1995-11-29 Casimir Colin Materials and methods relating to the transfer of nucleic acid into stem cells
WO1997016169A1 (en) 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
NZ331186A (en) 1996-02-02 2000-04-28 Alza Corp Osmotically driven sustained delivery drug delivery capsule
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
CA2213906A1 (en) 1996-09-23 1998-03-23 Dusica Maysinger Pharmaceutical composition and method for neuron rescue in ischemic stroke
US6258119B1 (en) 1996-11-07 2001-07-10 Myocardial Stents, Inc. Implant device for trans myocardial revascularization
US5931810A (en) * 1996-12-05 1999-08-03 Comedicus Incorporated Method for accessing the pericardial space
US6443949B2 (en) * 1997-03-13 2002-09-03 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
DE69837491T2 (de) * 1997-07-03 2008-01-17 Osiris Therapeutics, Inc. Menschliche mesenchymale stammzellen aus peripherem blut
US6093531A (en) * 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
US6251418B1 (en) 1997-12-18 2001-06-26 C.R. Bard, Inc. Systems and methods for local delivery of an agent
US7078387B1 (en) * 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
WO2002030443A2 (en) 2000-10-11 2002-04-18 The Wistar Institute Regulation of human skin healing
EP1379197A4 (en) * 2001-03-23 2009-06-03 Durect Corp DISPOSAL OF MEDICINAL PRODUCTS OF DELAYED RELEASE DEVICES IMPLANTED IN MYOKARD TISSUE OR PER ICARDROOM
US7605128B2 (en) * 2002-02-14 2009-10-20 Buck Institute For Age Research Neurogenerative or neurotrophic factors for mitigating a symptom of ischemia
US20070238675A1 (en) * 2003-08-11 2007-10-11 Phillips M I Stem Cell Beacon
WO2005053729A1 (en) 2003-11-26 2005-06-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stem cell factor for inducing neural stem cell migration to areas of neurological injury
WO2005082440A1 (en) 2004-02-26 2005-09-09 V-Kardia Pty Ltd Isolating cardiac circulation
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114450013A (zh) * 2019-04-12 2022-05-06 爱莫里大学 用于促进造血细胞的细胞毒性的组合物和方法

Also Published As

Publication number Publication date
US20090304636A1 (en) 2009-12-10
AU2006315601A1 (en) 2007-05-24
JP2009517343A (ja) 2009-04-30
US8404653B2 (en) 2013-03-26
EP1948246A2 (en) 2008-07-30
CA2629775A1 (en) 2007-05-24
WO2007059010A2 (en) 2007-05-24
EP1948246A4 (en) 2010-04-28
WO2007059010A3 (en) 2009-04-30
EP1948246B1 (en) 2017-05-03

Similar Documents

Publication Publication Date Title
Johnson et al. Approaches to therapeutic angiogenesis for ischemic heart disease
Mitsos et al. Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials
AU2008232739B2 (en) Method of treating ischemic disorders
JP2006509043A (ja) 細胞に基づくｖｅｇｆ送達
US20090209630A1 (en) Gene delivery formulations and methods for treatment of ischemic conditions
Thiagarajan et al. Angiogenic growth factors in myocardial infarction: a critical appraisal
JP2010174017A (ja) Ｆｇｆの脈管形成的に有効な単位用量および投与方法
JP2003525222A (ja) Ｉｌ−１２をコードする核酸分子の腫瘍内投与
JP2012100670A (ja) 幹細胞をホーミングさせるためのｃｃｒリガンド
Bobek et al. Gene therapy of the ischemic lower limb—Therapeutic angiogenesis
US8404653B2 (en) Membrane bound stem cell factor therapy for ischemic heart
JP2017500316A (ja) ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復する方法
JP4111950B2 (ja) 自家骨髄の心筋内注射
Mikhail et al. Stimulating erythropoiesis: future perspectives
JP2025534734A (ja) 心筋細胞を保存及び保護し、心損傷後の心筋線維化を軽減する方法
KR20210133947A (ko) 디프테리아 독소-인간 인터루킨-3 접합체를 다른 제제와 조합하여 사용해서 골수증식성 신생물을 치료하는 조합 치료 방법
CN105264071B (zh) 用于治疗缺血组织的sdf-1递送
Sprengers et al. Growth factor and cell therapy in patients with critical limb ischemia
JP2011529452A (ja) 抗血管新生薬としての可溶性ｉｇｆ受容体
Beohar et al. Cytokine treatment for cardioprotection and cardiac regeneration
Donnelly et al. 8 Emerging Therapies for Chronic Lower Limb Ischemia (Novel Strategies Using Growth
Wnek et al. Gene-Activated Matrix/Neil Davies
Shohet Cardiovascular gene therapy: Angiogenesis and beyond

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20091021